Harvard CRISPR pioneer Chad Cowan launches $78M stem cell play

One of the scientific founders of CRISPR Therapeutics AG (Nasdaq: CRSP) is embarking on a mission to solve a longstanding problem in stem cell therapy: ensuring that the body does not mount an immune response to the foreign cells. He's got nearly $80 million to help him do it. Chad Cowan, a Harvard Stem Cell Institute professor and a serial entrepreneur whose discoveries helped launch CRISPR Therapeutics as well as Sana Biotechnology, has found a way to "cloak" engineered stem cells. Now, he is…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news